Please ensure Javascript is enabled for purposes of website accessibility

Why Eli Lilly Stock Is Down Today

By Prosper Junior Bakiny – Jul 30, 2020 at 11:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were not impressed with the company's second-quarter results.

What happened?

Shares of the pharma giant Eli Lilly (LLY 7.36%) were down by 5.7% as of 11:28 a.m. EDT on Thursday, after the company reported mixed second-quarter results before the market opened today.

So what

There were a few things to appreciate about Eli Lilly's financial results. For instance, the company's adjusted net income of $1.7 billion was an increase of 24% compared with the prior-year quarter; adjusted earnings also increased by 26% to $1.89 per share. The company's EPS handily beat the average analyst estimate of $1.56. But revenue decreased by 2% year over year to $5.5 billion. Although Lilly reported higher sales volumes, these were offset by lower realized prices for some of its products.

In other good news for investors, the company raised its 2020 guidance, and now expects its adjusted EPS to come in between $7.20 to $7.40, up from its previous estimate of $6.70 to $6.90.

Five downward pointing arrows on a blackboard.

Image source: Getty Images.

Now what 

Even with today's losses, Lilly's stock is up by more than 15% year to date. The healthcare company owes this performance in part to its efforts to develop a treatment for COVID-19. In June, it started three separate clinical trials for potential therapies for the disease.

Beyond its coronavirus-related efforts, the pharma giant boasts several exciting opportunities. In particular, its cancer treatment Verzenio recently scored a major win in a phase 3 study. Eli Lilly could add a new indication to this drug (whose sales are growing rapidly already) relatively soon. In short, despite the company's mixed quarterly update, the stock is still worth considering. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$334.00 (7.36%) $22.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.